Synthesis of conformationally constrained 5,6,7,8-tetrahydroimidazo[1,5-a]pyridine inhibitors of Farnesyltransferase

Organic Letters

Volumn 2, Issue 22, 2000, Pages 3473-3476

  Dinsmore, Christopher J ^a   Zartman, C Blair ^a   Baginsky, Walter F ^a   O'Neill, Timothy J ^a   Koblan, Kenneth S ^a   Chen, I Wu ^a   McLoughlin, Debra A ^a   Olah, Timothy V ^a   Huff, Joel R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; ENZYME INHIBITOR; FARNESYL TRANS TRANSFERASE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; TRANSFERASE;

ANIMAL; ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; CONFORMATION; DOG; DRUG ANTAGONISM; ORAL DRUG ADMINISTRATION; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADMINISTRATION, ORAL; ALKYL AND ARYL TRANSFERASES; ANIMALS; DOGS; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; IMIDAZOLES; INDICATORS AND REAGENTS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PYRIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034597510     PISSN: 15237060     EISSN: None     Source Type: Journal    
DOI: 10.1021/ol0002424     Document Type: Article

References (30)

1. (a) Kato, K.; Cox, A. D.; Hisaka, M. M.; Graham, S. M.; Buss, J. E. Proc. Natl. Acad. Sci. U.SA. 1992, 89, 6403-6407.
2. (b) Rowinsky, E. K.; Windle, J. L.; Von Hoff, D. D. J. Clin. Oncol. 1999, 17, 3631-3652.
3. (a) Oliff, A. Biochim. Biophvs. Acta 1999, 1423, C19-C30.
4. (b) End, D. W. Invest. New Drugs 1999, 17, 241-258.
5. (c) Gibbs, J. B. J. Clin. Invest. 2000, 105, 9-13.
6. (a) Williams, T. M.; Dinsmore. C. J.; Bergman, J. M.; Hutchinson, J. H.; MacTough, S. C.; Stump, C. S.; Wei, D. D.; Zartman, C. B.; Bogusky, M. J.; Chen, I.-W.; Culberson, J. C.; Koblan, K. S.; Kohl, N. E.; Lobell, R. B.; Motzel, S. L.; Salata, J. J.; Gibbs, J. B.; Graham, S. L.; Hartman, G. D.; Oliff, A. I.; Huff, J. R. Abstracts of Papers, 216th National Meeting of the American Chemical Society, Boston, MA, 1998, American Chemical Society: Washington, DC, 1998; MEDI 309.
7. (b) Manuscript in preparation.
8. In liver microsome incubation studies. 1 suffers N-dealkylations of the imidazole and piperazinone rings (unpublished results, ref 3b).
9. (a) H2 antagonists: Durant, G. J.; Loynes, J. M.; Wright, S. H. B. J. Med. Chem. 1973, 16, 1272-1276.
10. (b) Cardiotonics: Davey, D.; Erhardt, P. W.; Lumma, W. C., Jr.; Wiggins, J.; Sullivan, M.; Pang, D.; Cantor, E. J. Med. Chem. 1987, 30, 1337-1342.
11. (c) Aromatase inhibitors: Browne, L. J.; Gude, C.; Rodriguez, H.; Steele, R. E.; Bhatnager, A. J. Med. Chem. 1991, 34, 725-736.
12. (d) A-II antagonists: Huang, H.-C.; Chamberlain, T. S.; Olins, G. M.; Corpus, V. M.; Chen, S. T.; McMahon, E. G.; Palomo, M. A.; Blaine, E. H.; Manning, R. E. Bioorg. Med. Chem. Lett. 1994, 4, 2591-2596.
13. (e) Glycosidase inhibitors: Frankowski, A.; Deredas, D.; Nouen, D. L.; Tschamber, T.; Streith, J. Helv. Chim. Acta 1995, 78, 1837 -1842.
14. (f) 5-HT3 antagonists: Ohta, M.; Suzuki, T.; Koide, T.; Matsuhisa, A.; Furuya, T.; Miyata, K.; Yanagisawa, I. Chem. Pharm. Bull. 1996, 44, 991-999.
15. Davey, D. D. J. Org. Chem. 1987, 52, 1863-1867.
16. For the related Pictet-Spengler cyclization of histamine derivatives with aldehydes, see: (a) Heyl, D.; Luz, E.; Harris, S. S.; Folkers, K. J. Am. Chem. Soc. 1948, 70, 3669.
17. (b) Jouanisson, A.; Chavignon, O.; Couquelet, J.; Teulade, J.-C.; Chabard, J.-L.; Dauphin, G. Heterocycles 1995, 41, 21-28.
18. (c) Hutchins, S. M.; Chapman, K. T. Tetrahedron Lett. 1996, 37, 4865-4868.
19. 3 (1.5 equiv) in DMF at room temperature for 4 h (62% for 8b).
20. Mancuso, A. J.; Huang, S.-L.; Swern, D. J. Org. Chem. 1978, 43, 2480.
21. Weissman, S. A.; Lewis, S.; Askin, D.; Volante, R. P.; Reider, P. J. Tetrahedron Lett. 1998, 39, 7459-7462.
22. 4 (1.00 g, 8.3 mmol). The reaction was heated to reflux for 1.5 h, cooled to room temperature, diluted with dichloromethane (300 mL), filtered, and concentrated in vacuo. Purification by flash chromatography (6 × 15 cm silica gel, 40 → 80% acetone/dichloromethane) provided 12 (276 mg, 19%) and trans-2 (455 mg, 31%), both as pale yellow foams.
23. +) 446.1742, found 446.1732.
24. Hoffman, R. W. Angew. Chem., Int. Ed. Engl. 1992, 31, 1124 and references therein.
25. For assay conditions, see: Graham, S. L.; deSolms, S. J.; Kohl, N. E.; Mosser, S. D.; Oliff, A. I.; Pompliano, D. L.; Rands, E.; Breslin, M. J.; Deanna, A. A.; Garsky, V. M.; Scholz, T. H.; Gibbs, J. B.; Smith, R. L. J. Med. Chem. 1994, 37, 725-737.
26. The FTase inhibitory activity and dog pharmacokinetic (PK) properties of 1 and the corresponding 2-methylimidazole analogue of 1 are very similar, suggesting that the methyl groups in trans-13 and cis-13 contribute little to their inhibitory and PK activities (Merck Research Laboratories, unpublished results).
27. (a) Molecular modeling results, with relative energies in kcal/mol shown in parentheses: trans-13 diequatorial half-chair (0.00); trans-13 diaxial half-chair (1.56); cis-13 equatorial-)ArCN) - axial-(piperazinone) half-chair (0.18); cis-13 axial-(ArCN) - equatorial-(piperazinone) half-chair (0.59); cis-13 diaxial boat (5.46). Conformations were generated using the metric matrix distance geometry algorithm JG (S. Kearsley, Merck Research Laboratories, unpublished). The structures were subjected to energy-minimization within Macromodel (ref 15b) using the MMFF force field.
28. (b) Mohamadi, F.; Richards, N. G. J.; Guida, W. C.; Liskamp, R.; Caufield, C.; Chang, G.; Hendrickson, T.; Still, W. C. J. Comput. Chem. 1990, 11, 440-467.
29. For the protocol for PK analysis, see: Olah, T. V.; McLoughlin, D. A.; Gilbert, J. D. Rapid Commun. Mass Spectrom. 1997, 11, 17-23.
30. 1/2 10.3 h) relative to 1 (2 mpk: CL = 10.6 mL/min/kg).